ライフサイエンスコーパス: second cancer

1 onsequences (accelerated atherosclerosis and second cancer).

2 k of death as a result of cardiac disease or second cancer.

3 p is associated with a substantive risk of a second cancer.

4 second cancer, especially an obesity-related second cancer.

5 second primary cancer or an obesity-related second cancer.

6 diagnosis increases mortality and risk for a second cancer.

7 kely includes recurrences misclassified as a second cancer.

8 s and a predisposition to the development of second cancers.

9 ment of de novo leukaemia or therapy-related second cancers.

10 Two of the 86 (2.3%) patients developed second cancers.

11 We have therefore examined the incidence of second cancers.

12 cessary to reduce the risk of recurrence and second cancers.

13 has been accompanied by an increased risk of second cancers.

14 milar risks of circulatory complications and second cancers.

15 ociated with an increased risk of developing second cancers.

16 nd reduction in numbers of germline mutation second cancers.

17 ure to TKIs increases the risk of developing second cancers.

18 the development of ALL and treatment-related second cancers.

19 er, substantially increase the risk of later second cancers.

20 pse after response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-sided P =

21 (HR, 0.90; 95% CI, 0.61 to 1.32) followed by second cancers (13.6% of deaths; HR, 1.24; 95% CI, 0.49

22 mportant, including the risk of developing a second cancer after radiotherapy.

23 ly. Seven (14%) and 6 (2%) patients reported second cancers after treatment with eBEACOPP and ABVD, r

24 We compared the risk of a second cancer among these patients with the risk that wa

25 This study quantified the risk of second cancers among 16 367 patients with CLL in the pop

26 Understanding risk factors for second cancers among cancer survivors is crucial.

27 weight management and increase awareness of second cancers among physicians and cancer survivors.

28 ave more than twice the risk of developing a second cancer and an increased frequency of certain canc

29 a on HL relapse, late recurrence, and excess second cancer and cardiac late-effects mortality were es

30 with radiotherapy include increased risk of second cancer and cardiovascular disease.

31 sted that approximately 2% of all the 64 747 second cancers and 7% of the 15 813 excess second cancer

32 significantly associated with mortality from second cancers and other causes, whereas menopausal horm

33 The 15-year cumulative risks of all second cancers and secondary ANLL were 37% and 17%, resp

34 We discuss recent insights regarding second cancers and the relevance of infectious complicat

35 re at high risk of potentially life-limiting second cancers and treatment-associated cardiovascular d

36 Second cancers and treatment-related toxicities were sim

37 noma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or af

38 onger and are at risk for cancer recurrence, second cancers, and complications from treatment.

39 sis and pinealoblastoma, minimizes long-term second cancers, and has few systemic and no ocular toxic

40 (PFS), time to local failure, development of second cancers, and severe grade 3 or higher adverse eve

41 zoxane may reduce treatment efficacy, induce second cancers, and thus compromise overall survival amo

42 ancer; (iv) surveillance for recurrences and second cancers; and (v) cancer prevention and overall he

43 A relatively small proportion of second cancers are related to radiotherapy in adults, su

44 , 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17

45 he first cancer sites the RR of developing a second cancer associated with radiotherapy exceeded 1, a

46 fied either the p.His1047Leu alteration or a second cancer-associated alteration, p.His1047Arg, in ni

47 Cumulative incidence (+/-SE) of a second cancer at 50 years after diagnosis was 51.0% (+/-

48 Twenty-six patients developed a second cancer at least 6 months after the HCL diagnosis

49 experience significantly increased risks of second cancers at various sites for 2 to 3 decades.

50 We aimed to estimate the proportion of second cancers attributable to radiotherapy in adults wi

51 also common after HCT, including infections, second cancers, bone loss, and cardiovascular, pulmonary

52 ation, was associated with more toxicity and second cancers but a significantly longer time to diseas

53 complications, such as cardiac mortality and second cancers, but long-term efficacy is unclear.

54 oplasm (MPN) are prone to the development of second cancers, but the factors associated with these ev

55 increased risk of early mortality related to second cancers, cardiac disease, and infection.

56 Second, cancer cells maintain the CAF phenotype via acti

57 as a significant excess risk of all types of second cancers combined (SIR, 3.40; 95% CI, 1.55-6.45),

58 survivors had a higher risk of developing a second cancer compared with an age- and sex-matched gene

59 ere associated with earlier age at first and second cancer compared with notDNE_notLOF and DNE_notLOF

60 had an increased probability of developing a second cancer compared with the general population.

61 nt), death (competing event), diagnosis of a second cancer (competing event), emigration (censoring e

62 ciated with increased risk for infection and second cancers, contributing to morbidity and mortality

63 Fifty-three patients developed second cancers (control, n = 32; DC, n = 21; leukemia: 2

64 to risk estimates consistent with high-dose second-cancer data.

65 or cancer induction at high doses and recent second-cancer data.

66 after chemotherapy may reduce occurrence of second cancers decades later.

67 identify the cell cycle-regulated genes in a second cancer-derived cell line and provide a comprehens

68 eservoir from which proliferative lesions or second cancers develop once additional genetic abnormali

69 ival, hematologic toxicity, ocular toxicity, second cancer development and electroretinogram response

70 All second cancers diagnosed in patients included in the TME

71 son comorbidity index, cancer treatment, and second cancer diagnosis before the start of follow-up.

72 f the following events: CBC diagnosis, other second cancer diagnosis, death, last tumor registry foll

73 iagnosis were at higher risk of developing a second cancer, especially an obesity-related second canc

74 as well as the mutually increased risks for second cancer for both organs, grain fiber and whole gra

75 There is a substantial risk of a second cancer for persons with hereditary retinoblastoma

76 Moreover, modeling second cancers gives unique insights into human carcinog

77 due to longer patient survival times, these second cancers have become of increasing concern.

78 nly orchiectomy, had an increased risk for a second cancer (hazard ratio [HR], 3.2; 95% CI, 1.9 to 5.

79 rly follow-up forms recorded any recurrence, second cancer, hospital admission, or death.

80 HCL, there was an increase in the number of second cancers; however, it did not reach statistical si

81 ere diagnosed with prostate cancer without a second cancer in 12 months from January 2011 to December

82 ed the long-term probability of developing a second cancer in a large pooled cohort of patients treat

83 incidence ratios and cumulative incidence of second cancer in HL survivors and compared the standardi

84 Results Overall, the risk of a second cancer in HL survivors was increased 2.39-fold (9

85 n chronic inflammation, atherosclerosis, and second cancer in MPNs favors early intervention at the t

86 Relative risks (RRs) for second cancer in patients treated with radiotherapy vers

87 ture atherosclerosis," clonal evolution, and second cancer in patients with MPNs.

88 e that OC or PMH use increases the risk of a second cancer in the contralateral breast.

89 8 to 5.4), and the cumulative incidence of a second cancer in the study cohort at 40 years was 48.5%

90 definitively assess their risk of developing second cancers in a lifetime.

91 ratios of lung, breast, colorectal, and all second cancers in HL survivors with and without a site-s

92 tion is used in cancer therapy it can induce second cancers in nearby organs.

93 the literature confirmed some of the common second cancers in retinoblastoma survivors but found lit

94 what extent these strategies reduce risk of second cancers in such patients.

95 7 second cancers and 7% of the 15 813 excess second cancers in the cohort may be attributable to adju

96 a high incidence of apparently metachronous second cancers in the first 2 years after resection.

97 However, recent studies of radiation-induced second cancers in the lung and breast, covering a very w

98 m diagnosis, 66 patients (4.6%) developed 80 second cancers, including skin (31%), prostate (15%), me

99 derstand the contribution of radiotherapy to second cancer induction and pursue well-coordinated effo

100 Estimating the risk of solid second cancers involves modeling: because of long latenc

101 Second cancer is the leading cause of death in long-term

102 Second, cancer itself serves as a risk factor for vascul

103 Participants were followed until death, second cancer, loss to follow-up, 10 years after diagnos

104 may be less frequent long-term effects (eg, second cancers, lymphedema, osteoporosis).

105 Comorbidities, severe adverse events, second cancers, management of relapse and death as a res

106 or other interventions to reduce the rate of second cancers may be valuable.

107 on the different causes of death, including second cancer mortality, noncancer mortality, and cause-

108 cause many acute and late complications (eg, second cancers, neurocognitive deficits, endocrine disor

109 The number of second cancers observed was compared with the number exp

110 Two thousand one hundred fifty-three second cancers (observed-to-expected ratio [O/E] = 2.3;

111 Second cancers occur in a small percentage of patients r

112 Overall, 1,296 second cancers occurred against 1,014 expected [observed

113 ages (10 to 16 years), the largest number of second cancers occurred in the digestive tract (O/E = 19

114 nitially with low-dose TBI was monitored for second cancer occurrence.

115 SIRs for second cancers of the colon, soft tissue, melanoma, and

116 age points in suitable women but can cause a second cancer or heart disease decades later.

117 rial and investigated whether they developed second cancers or had histologic residual disease.

118 No patient developed metastatic disease, second cancer, or trilateral retinoblastoma and all eyes

119 Interventions to prevent second cancers, particularly PCM, may offer substantial

120 sing data from the American Cancer Society's second Cancer Prevention Study (CPS II), a cohort study

121 No differences were found in second cancer probability between patients who were trea

122 The second cancer profiles among cervical SCC and AC survivo

123 The awareness of an increased risk of second cancer remains crucial for survivors of Hodgkin's

124 n the late 1980s, on the long-term risk of a second cancer remains unknown.

125 Data on smoking and second cancer risk among cancer survivors are limited.

126 king before first cancer diagnosis increases second cancer risk among cancer survivors, and elevated

127 Factors contributing to second cancer risk include the carcinogenic effects of i

128 Second cancer risk peaked 5 to 9 years after chemotherap

129 Second cancer risk was high during all follow-up interva

130 or differences translate into differences in second cancer risk.

131 Second, cancer risk among antireflux surgery patients wa

132 We sought to quantify the second cancer risks and to investigate the impact of fam

133 Second cancer risks for patients who received chemothera

134 d susceptibility, may contribute to elevated second cancer risks in colorectal cancer survivors compa

135 creasing concern regarding radiation-related second-cancer risks in long-term radiotherapy survivors

136 CI, 1.29 to 1.34) and AC survivors (n = 920 second cancers; SIR, 1.29; 95% CI, 1.22 to 1.38).

137 mong both cervical SCC survivors (n = 10,559 second cancers; SIR, 1.31; 95% CI, 1.29 to 1.34) and AC

138 n, can be important at the doses relevant to second cancer situations.

139 Failures are due to relapse, toxicity, and second cancers such as therapy-related myeloid leukemia

140 Germline mutations of a second cancer susceptibility gene BRCA1, are associated

141 BT had no higher probability of developing a second cancer than patients who were treated with surger

142 complex (MHC) loci, confirming that it is a second cancer that can be transmitted between devils as

143 o in the burden of "late effects," including second cancers, that compromise quality of life and limi

144 late relapse of disease, the development of second cancers, the effect of the disease and treatment

145 ge 0 are at increased risk of infections and second cancers, the risk of progression requiring treatm

146 eath has been from HD: five patients died of second cancers, two of cardiac disease, and one of alcoh

147 The RR of developing a second cancer was 15.4 (95% confidence interval [CI], 10

148 in the RT group the actuarial frequency of a second cancer was 16% at 20 years.

149 The risk of a second cancer was 2.2 times higher than the expected ris

150 The standardized incidence ratio for any second cancer was 2.98 (95% CI, 2.82 to 3.14).

151 The risk of a second cancer was assessed by calculating the standard i

152 A nonbreast second cancer was detected in 73 patients (8.4%), and th

153 The risk of second cancer was lower than expected (observed-to-expec

154 Relative risk (RR) of second cancer was raised after chemotherapy alone (RR, 2

155 The time interval from first to second cancer was shorter among carriers whose first can

156 The risk of all second cancers was 1.3-fold higher for HL survivors with

157 The number of second cancers was compared with the number expected fro

158 ned by histology analysis and development of second cancers was documented.

159 r Registry, the SIR for risk of all types of second cancers was similar to that in SEER 9 (SIR, 3.45;

160 LFSPRO.MPC model to predict the onset of the second cancer, we obtained an AUC of 0.70 (95% CI, 0.58

161 , local recurrence-free survival and time to second cancer were both: research 96.4%, control 87.8% (

162 Thrombotic events after MPN and before second cancer were higher in cases than in controls (11.

163 The most common locations of second cancer were skin (20 cases / 15%), breast (17 cas

164 With a median follow-up of 19.1 years, 1055 second cancers were diagnosed in 908 patients, resulting

165 Significantly increased risks of second cancers were observed in all HD age groups.

166 No second cancers were observed in the CMT group; in the RT

167 l details on incident heart failure (HF) and second cancers were presented.

168 Similar numbers of cardiac events and second cancers were recorded in the groups.

169 Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients tr

170 The most important cause of death was non-TC second cancer with an overall SMR of 1.53 (95% CI, 1.35

171 1.35) were at increased risk of developing a second cancer with the same aetiology, whereas having ha